Syndax Pharmaceuticals, Inc. (SNDX)
| Market Cap | 850.77M -41.7% |
| Revenue (ttm) | 289.68M +160.3% |
| Net Income | -209.48M |
| EPS | -2.37 |
| Shares Out | 90.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,179,737 |
| Open | 9.73 |
| Previous Close | 9.54 |
| Day's Range | 9.11 - 9.85 |
| 52-Week Range | 9.11 - 25.59 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 35.45 (+275.13%) |
| Earnings Date | Nov 2, 2026 |
About SNDX
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination... [Read more]
Financial Performance
In 2025, Syndax Pharmaceuticals's revenue was $172.35 million, an increase of 627.84% compared to the previous year's $23.68 million. Losses were -$285.42 million, -10.46% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price target is $35.45, which is an increase of 275.13% from the latest price.
News
Syndax Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026
Revuforj growth is expected from new patient starts and longer post-transplant maintenance, with greater revenue impact anticipated in 2027. Frontline trials and differentiated EGFR and next-generation menin programs advance the next growth phase.
Syndax Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Revuforj and Niktimvo are growing, with transplant, maintenance and earlier-line use supporting expansion. Key catalysts include frontline and combination data in 2027, a Niktimvo pivotal readout in early 2028, and new pipeline programs.
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in connectio...
Syndax selloff yesterday an overreaction, says H.C. Wainwright
H.C. Wainwright views the 25% selloff yesterday in shares of Syndax (SNDX) following the ASH abstract release “as an overreaction that obscures meaningful progress across its own programs.” Johnson &…
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November ...
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company ...
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax's scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multipl...
Syndax price target lowered to $36 from $38 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Syndax (SNDX) to $36 from $38 and keeps a Buy rating on the shares. The firm sees the rebound in Revuforj patient…
Syndax Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue rose 82% YoY to $83.3 million, led by Revuforj and Niktimvo. Management expects post-transplant treatment resumption to reinforce Revuforj growth, while advancing frontline trials and new pipeline programs.
Syndax Pharmaceuticals Earnings release: Q3 2026
Syndax Pharmaceuticals released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Syndax Pharmaceuticals Quarterly report: Q3 2026
Syndax Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 2, 2026.
Syndax Pharmaceuticals Slides: Q3 2026
Syndax Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Syndax reports Q3 EPS (55c), consensus (48c)
Reports Q3 revenue $83.298M, consensus $81.81M. “We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax (SNDX). Revuforj net revenue grew to $61 m...
Syndax appoints Ondrey as Chief Financial Officer
Syndax (SNDX) Pharmaceuticals announced the appointment of Aaron Ondrey as Chief Financial Officer, effective November 9, 2026. Ondrey brings to Syndax more than 25 years of financial and operational ...
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT...
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commerc...
Syndax's Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia -
Syndax Announces Participation in November Investor Conferences
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M...
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will repo...
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $SNDX--SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (r...
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies investor...
Syndax valuation unchanged after trial miss, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating on Syndax (SNDX) with a $38 price target after the Phase 2 study of axatilimab in idiopathic pulmonary fibrosis missed the endpoint. “While disappointing,…
Syndax selloff brings attractive entry point, says Citi
Citi views the selloff in Syndax (SNDX) shares after the Phase 2 study of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint as creating an attractive entry point. Citi…
Syndax price target lowered to $23 from $26 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on Syndax (SNDX) to $23 from $26 and keeps a Buy rating on the shares after the company announced MAXPIRe, its…